Immuneering Corp
IMRX6.420USD
+0.510+8.63%
Market hours （ET）Quotes delayed by 15 min
407.56MMarket Cap
LossP/E TTM
More Details of Immuneering Corp Company
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Immuneering Corp Info
Ticker SymbolIMRX
Company nameImmuneering Corp
IPO dateJul 30, 2021
CEOZeskind (Benjamin J)
Number of employees66
Security typeOrdinary Share
Fiscal year-endJul 30
Address245 Main Street, Second Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16175008080
Websitehttps://immuneering.com/
Ticker SymbolIMRX
IPO dateJul 30, 2021
CEOZeskind (Benjamin J)
Company Executives of Immuneering Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.53K
+1.10%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
23.34K
+3.55%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Dr. Igor Matushansky, M.D., Ph.D.
Dr. Igor Matushansky, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Diana F. Hausman, M.D.
Dr. Diana F. Hausman, M.D.
Independent Director
Independent Director
--
--
Mr. Michael D. Bookman
Mr. Michael D. Bookman
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
27.53K
+1.10%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
23.34K
+3.55%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.46%
Empery Asset Management, L.P.
6.37%
HBM Partners AG
5.65%
Zeskind (Benjamin J)
4.97%
Merrin Investors, L.L.C.
4.29%
Other
65.27%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.46%
Empery Asset Management, L.P.
6.37%
HBM Partners AG
5.65%
Zeskind (Benjamin J)
4.97%
Merrin Investors, L.L.C.
4.29%
Other
65.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.01%
Individual Investor
9.40%
Investment Advisor/Hedge Fund
9.29%
Corporation
8.49%
Hedge Fund
7.26%
Venture Capital
1.57%
Research Firm
0.27%
Other
33.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
154
21.91M
38.01%
+11.24M
2025Q2
159
13.40M
37.24%
-6.12M
2025Q1
161
13.19M
41.31%
-6.04M
2024Q4
164
13.00M
41.85%
-6.73M
2024Q3
162
13.05M
42.83%
-8.70M
2024Q2
161
18.30M
60.87%
-2.07M
2024Q1
151
20.58M
69.02%
-6.37M
2023Q4
145
24.26M
82.88%
-4.62M
2023Q3
147
25.15M
85.99%
-3.63M
2023Q2
142
25.50M
87.18%
+568.32K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
8.79M
15.24%
+8.57M
+3876.04%
Sep 30, 2025
HBM Partners AG
3.65M
6.32%
+3.65M
--
Sep 26, 2025
Zeskind (Benjamin J)
3.21M
5.56%
+10.00K
+0.31%
Jul 02, 2025
Merrin Investors, L.L.C.
2.77M
4.8%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
1.06M
1.83%
--
--
Jun 30, 2025
Carpenter (Robert J)
1.15M
1.99%
--
--
Apr 17, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
T Rowe Price Small-Mid Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immuneering Corp?
The top five shareholders of Immuneering Corp are:
Fidelity Management & Research Company LLC holds 8.79M shares, accounting for 15.24% of the total shares.
HBM Partners AG holds 3.65M shares, accounting for 6.32% of the total shares.
Zeskind (Benjamin J) holds 3.21M shares, accounting for 5.56% of the total shares.
Merrin Investors, L.L.C. holds 2.77M shares, accounting for 4.80% of the total shares.
The Vanguard Group, Inc. holds 1.06M shares, accounting for 1.83% of the total shares.
Fidelity Management & Research Company LLC holds 8.79M shares, accounting for 15.24% of the total shares.
HBM Partners AG holds 3.65M shares, accounting for 6.32% of the total shares.
Zeskind (Benjamin J) holds 3.21M shares, accounting for 5.56% of the total shares.
Merrin Investors, L.L.C. holds 2.77M shares, accounting for 4.80% of the total shares.
The Vanguard Group, Inc. holds 1.06M shares, accounting for 1.83% of the total shares.
What are the top three shareholder types of Immuneering Corp?
The top three shareholder types of Immuneering Corp are:
Fidelity Management & Research Company LLC
Empery Asset Management, L.P.
HBM Partners AG
Fidelity Management & Research Company LLC
Empery Asset Management, L.P.
HBM Partners AG
How many institutions hold shares of Immuneering Corp (IMRX)?
As of 2025Q3, 154 institutions hold shares of Immuneering Corp, with a combined market value of approximately 21.91M, accounting for 38.01% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.77%.
What is the biggest source of revenue for Immuneering Corp?
In --, the -- business generated the highest revenue for Immuneering Corp, amounting to -- and accounting for --% of total revenue.
